|
Praveen Tyle, Ph.D. is currently Senior Vice President, Research and Development and Chief Scientific Officer of Bausch and Lomb, the global eye health care company. He is experienced in moving products from laboratory to market, as well as drug development. Prior, he was Group Vice President Pharmaceutical Sciences and Manufacturing at Biovail Corporation from 2003 on. Prior to that position, Dr. Tyle spent 4 years at Pharmacia Corporation, most recently as Vice President and Global Head Pharmaceutical Sciences. In total, Dr. Tyle has approximately 20 years of drug development and commercialization experience. He began his professional career as a formulations research chemist in drug delivery research with American Cyanamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). Dr. Tyle holds academic appointments as Adjunct Professor of Pharmacy at the University of Rhode Island and at the University of Houston, Texas. He is the editor of 7 books about drug development, holds several patents and is author of more than 120 technical and scientific papers and presentations. He received a Ph.D. degree in Pharmaceutics and Pharmaceutical Chemistry from the Ohio State University in 1984 and a Bachelor of Pharmacy degree from the Institute of Technology, Banaras Hindu University, India, in 1980. He is a member of the Council of Healthcare Advisors, the Advisory Board of Oakland University Center for Biomedical Research, and is a scientific advisor to CB Health Ventures of Boston and Epimmune, Inc., of San Diego. He also serves on the Boards of Directors of Orient Europharma Co. Ltd., Taiwan, and Interpath Pharmaceuticals, Houston.
| 